Catalysts About Traws Pharma Traws Pharma is a biotechnology company focused on developing next generation antiviral treatments and prophylactic agents for influenza. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Traws Pharma Traws Pharma is a clinical stage company focused on developing next generation antiviral treatments and prophylactic therapies for influenza. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Traws Pharma Traws Pharma is a clinical stage biopharmaceutical company developing oral antivirals for COVID 19 and pandemic influenza, alongside partnering opportunities in oncology. What are the underlying business or industry changes driving this perspective?Read more
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
